Why the study?
Pulmonary vasoconstriction significantly contributes to increased RV afterload in acute PE but is often untreated, and only limited clinical data evaluate pulmonary vasodilators.
What is the role and evidence for pulmonary vasodilation in the treatment of acute pulmonary embolism?
What is the role and evidence for pulmonary vasodilation in the treatment of acute pulmonary embolism?
This systematic review highlights the pathophysiological role of pulmonary vasoconstriction in acute pulmonary embolism and the potential, yet risky, therapeutic use of pulmonary vasodilators.
No takes yet. Share an insight, caveat, or question.
Caution against routine pulmonary vasodilator use in acute PE; leaves open selective human trials.
Lyhne et al. (2019) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: